Skip to main navigation Skip to search Skip to main content

Microfluidic chip-based cancer diagnosis and prediction of relapse by detecting circulating tumor cells and circulating cancer stem cells

  • Hyeon Yeol Cho
  • , Jin Ha Choi
  • , Joungpyo Lim
  • , Sang Nam Lee*
  • , Jeong Woo Choi*
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Detecting circulating tumor cells (CTCs) has been considered one of the best biomarkers in liquid biopsy for early diagnosis and prognosis monitoring in cancer. A major challenge of using CTCs is detecting extremely low-concentrated targets in the presence of high noise factors such as serum and hematopoietic cells. This review provides a selective overview of the recent progress in the design of microfluidic devices with optical sensing tools and their application in the detection and analysis of CTCs and their small malignant subset, circulating cancer stem cells (CCSCs). Moreover, discussion of novel strategies to analyze the differentiation of circulating cancer stem cells will contribute to an understanding of metastatic cancer, which can help clinicians to make a better assessment. We believe that the topic discussed in this review can provide brief guideline for the development of microfluidic-based optical biosensors in cancer prognosis monitoring and clinical applications.

Original languageEnglish
Article number1385
Pages (from-to)1-17
Number of pages17
JournalCancers
Volume13
Issue number6
DOIs
StatePublished - 2021.03.2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Circulating cancer stem cells
  • Circulating tumor cells
  • Early diagnosis
  • Liquid biopsy
  • Microfluidic platform
  • Optical sensing

Quacquarelli Symonds(QS) Subject Topics

  • Medicine
  • Biological Sciences

Fingerprint

Dive into the research topics of 'Microfluidic chip-based cancer diagnosis and prediction of relapse by detecting circulating tumor cells and circulating cancer stem cells'. Together they form a unique fingerprint.

Cite this